Esophageal AchalasiaPhase 3NCT07425977
Transverse vs Longitudinal Mucosal Incision During POEM
A Phase 3 study testing Transverse Mucosal Incision During POEM and Longitudinal Mucosal Incision During POEM in people with Esophageal Achalasia and Spastic Esophageal Motility Disorders, run by Universidad Nacional de Colombia at 1 site in Colombia.
Trial summary
Peroral endoscopic myotomy (POEM) is a minimally invasive endoscopic procedure used to treat achalasia and other spastic esophageal motility disorders. A key step in POEM is creating a small opening in the esophageal lining (mucosal incision) to enter the submucosal tunnel. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Esophageal Achalasia, Spastic Esophageal Motility Disorders
- What is being tested?
- Transverse Mucosal Incision During POEM and Longitudinal Mucosal Incision During POEM
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 140 participants
- Where
- 1 siteColombia
- Study dates
- 22 Feb 2026to 2 Aug 2026
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Diagnosis of achalasia or other spastic esophageal motility disorders with an indication for POEM
- ASA physical status I-III
- Ability to provide informed consent
Who cannot join
- Prior myotomy or major esophageal surgery
- Uncorrectable coagulopathy
- Pregnancy
- Active systemic infection
- Contraindication to anesthesia
- Any situation predicting technical inability to perform POEM
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Transverse Versus Longitudinal Mucosal Incision in Peroral Endoscopic Myotomy: A Multicenter Randomized Clinical Trial
Peroral endoscopic myotomy (POEM) is a minimally invasive endoscopic procedure used to treat achalasia and other spastic esophageal motility disorders. A key step in POEM is creating a small opening in the esophageal lining (mucosal incision) to enter the submucosal tunnel. This study evaluates whether making that entry incision transverse (across the esophagus) versus longitudinal (along the esophagus) improves procedural efficiency without reducing safety.
This is a multicenter, randomized (1:1), parallel-group clinical trial conducted in three therapeutic endoscopy units in Colombia (Hospital Universitario del Valle and Clínica Versalles in Cali, and Clínica del Occidente in Bogotá). Adults (≥18 years) with an indication for POEM, ASA I-III, and ability to provide informed consent will be eligible; key exclusions include prior myotomy/major esophageal surgery, uncorrectable coagulopathy, pregnancy, active systemic infection, anesthesia contraindication, or anticipated technical inability to perform POEM.
Read more
All procedures are standardized: POEM under general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives and preset electrosurgical modes; hemostasis with Coagrasper® only if needed; and closure using standard through-the-scope (TTS) clips. Participants are randomly assigned to a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) or a 15 mm longitudinal mucosal incision. Full-procedure video is recorded for quality control and to allow objective timing, with blinded assessment of the primary outcome.
The primary outcome is the time (seconds) from the first mucosal cut to successful entry of the endoscope cap into the submucosal tunnel (advancing at least 1 cm). Secondary outcomes include need for hemostasis with Coagrasper®, number of clips required for complete closure, and early complications (including perforation and gas-related events such as capnoperitoneum requiring decompression and emphysema), monitored through 30 days.
Participants complete a screening/preoperative visit (up to 30 days before), undergo the POEM procedure, have early in-hospital/discharge assessment (days 1-2), and receive safety follow-up contacts at approximately 1 week and day 30.
Risks are those expected from standard POEM and peri-anesthesia care (e.g., bleeding, perforation, infection, and gas-related complications), and participants may not directly benefit clinically. However, the transverse incision may shorten access and closure time and reduce resource use without increasing short-term complications.
The study will be conducted with written informed consent, confidentiality protections (pseudonymization and secure storage), and reporting of results in aggregate form.
- Being tested
- Transverse Mucosal Incision During POEM, Longitudinal Mucosal Incision During POEM
- Medical subject headings
- Esophageal Achalasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transverse Mucosal Incision During POEMProcedure or surgery
POEM performed with a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) for entry into the submucosal tunnel, under a standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded).
Longitudinal Mucosal Incision During POEMProcedure or surgery
POEM performed with a 15 mm longitudinal mucosal incision (parallel to the esophageal axis) for entry into the submucosal tunnel, under the same standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded).
| Study group | Role | What they receive |
|---|---|---|
| Transverse Mucosal Incision During POEM | Experimental | POEM performed with a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) for entry into the submucosal tunnel, under a standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded) Receives: Procedure: Transverse Mucosal Incision During POEM |
| Longitudinal Mucosal Incision During POEM | Active comparator | POEM performed with a 15 mm longitudinal mucosal incision (parallel to the esophageal axis) for entry into the submucosal tunnel, under the same standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded) Receives: Procedure: Longitudinal Mucosal Incision During POEM |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Effective Submucosal Tunnel Entry (Seconds)
Time (in seconds) from the first mucosal cut to effective entry of the endoscope cap into the submucosal tunnel, defined as allowing advancement of at least 1 cm.
Measured: During the POEM procedure (Day 0; intraoperative)
Secondary outcomes (2)
Bleeding Requiring Hemostasis With Coagrasper®
Proportion of procedures with bleeding that requires hemostasis using Coagrasper® (Yes/No).
Measured: During the POEM procedure (Day 0; intraoperative)
Procedure-Related Complications (Up to 30 Days)
Any complication related to the procedure, monitored through 30 days.
Measured: Up to 30 days after the procedure (contacts at ~1 week and Day 30; plus early assessment Days 1-2).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2026
- Study start22 Feb 2026 (estimated)
- Primary completion2 Jul 2026 (estimated)
- Study completion2 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Esophageal AchalasiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 140 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad Nacional de Colombia
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital San Rafael de Facatativá
- Responsible party
- Principal investigator, Juan Pablo Alzate, Universidad Nacional de Colombia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07425977
- Sponsor's protocol ID
- DE-F-254-V8
- Status last verified
- Feb 2026
- First submitted
- 16 Feb 2026
- Last updated
- 24 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Transverse Versus Longitudinal Mucosal Incision in Peroral Endoscopic Myotomy: A Multicenter Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07425977
- Acronym / sponsor ID
- DE-F-254-V8
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 140 participants (estimated)
- Lead sponsor
- Universidad Nacional de ColombiaUniversity, hospital or other
- Collaborators
- Hospital San Rafael de Facatativá
- Study start
- 22 Feb 2026 (estimated)
- Primary completion
- 2 Jul 2026 (estimated)
- Study completion
- 2 Aug 2026 (estimated)
- First posted
- 23 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Peroral endoscopic myotomy (POEM) is a minimally invasive endoscopic procedure used to treat achalasia and other spastic esophageal motility disorders. A key step in POEM is creating a small opening in the esophageal lining (mucosal incision) to enter the submucosal tunnel. This study evaluates whether making that entry incision transverse (across the esophagus) versus longitudinal (along the esophagus) improves procedural efficiency without reducing safety.
This is a multicenter, randomized (1:1), parallel-group clinical trial conducted in three therapeutic endoscopy units in Colombia (Hospital Universitario del Valle and Clínica Versalles in Cali, and Clínica del Occidente in Bogotá). Adults (≥18 years) with an indication for POEM, ASA I-III, and ability to provide informed consent will be eligible; key exclusions include prior myotomy/major esophageal surgery, uncorrectable coagulopathy, pregnancy, active systemic infection, anesthesia contraindication, or anticipated technical inability to perform POEM.
All procedures are standardized: POEM under general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives and preset electrosurgical modes; hemostasis with Coagrasper® only if needed; and closure using standard through-the-scope (TTS) clips. Participants are randomly assigned to a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) or a 15 mm longitudinal mucosal incision. Full-procedure video is recorded for quality control and to allow objective timing, with blinded assessment of the primary outcome.
The primary outcome is the time (seconds) from the first mucosal cut to successful entry of the endoscope cap into the submucosal tunnel (advancing at least 1 cm). Secondary outcomes include need for hemostasis with Coagrasper®, number of clips required for complete closure, and early complications (including perforation and gas-related events such as capnoperitoneum requiring decompression and emphysema), monitored through 30 days.
Participants complete a screening/preoperative visit (up to 30 days before), undergo the POEM procedure, have early in-hospital/discharge assessment (days 1-2), and receive safety follow-up contacts at approximately 1 week and day 30.
Risks are those expected from standard POEM and peri-anesthesia care (e.g., bleeding, perforation, infection, and gas-related complications), and participants may not directly benefit clinically. However, the transverse incision may shorten access and closure time and reduce resource use without increasing short-term complications.
The study will be conducted with written informed consent, confidentiality protections (pseudonymization and secure storage), and reporting of results in aggregate form.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Transverse Mucosal Incision During POEM | Experimental | Procedure: Transverse Mucosal Incision During POEMPOEM performed with a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) for entry into the submucosal tunnel, under a standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded) |
| Longitudinal Mucosal Incision During POEM | Active comparator | Procedure: Longitudinal Mucosal Incision During POEMPOEM performed with a 15 mm longitudinal mucosal incision (parallel to the esophageal axis) for entry into the submucosal tunnel, under the same standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- Diagnosis of achalasia or other spastic esophageal motility disorders with an indication for POEM
- ASA physical status I-III
- Ability to provide informed consent
Key exclusion criteria (6 listed)
- Prior myotomy or major esophageal surgery
- Uncorrectable coagulopathy
- Pregnancy
- Active systemic infection
- Contraindication to anesthesia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transverse Mucosal Incision During POEMPOEM performed with a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) for entry into the submucosal tunnel, under a standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded). | Procedure or surgery | Transverse Mucosal Incision During POEM |
| Longitudinal Mucosal Incision During POEMPOEM performed with a 15 mm longitudinal mucosal incision (parallel to the esophageal axis) for entry into the submucosal tunnel, under the same standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded). | Procedure or surgery | Longitudinal Mucosal Incision During POEM |
Primary outcome
Time to Effective Submucosal Tunnel Entry (Seconds)
Time frame: During the POEM procedure (Day 0; intraoperative)
Time (in seconds) from the first mucosal cut to effective entry of the endoscope cap into the submucosal tunnel, defined as allowing advancement of at least 1 cm.
2 secondary outcomes
Bleeding Requiring Hemostasis With Coagrasper®
Time frame: During the POEM procedure (Day 0; intraoperative)
Procedure-Related Complications (Up to 30 Days)
Time frame: Up to 30 days after the procedure (contacts at ~1 week and Day 30; plus early assessment Days 1-2).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Esophageal Achalasia
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 2
Full-thickness Versus Progressive Myotomy in Peroral Endoscopic Esophageal Myotomy in Achalasia: A Randomized Controlled Trial
Achalasia Cardia, Achalasia
RecruitingPhase 3
PREcision MEDicine In Achalasia (PREMEDIA)
Type I Achalasia, Type II Achalasia
RecruitingObservational study
PREcision MEDicine In Achalasia (PREMEDIA) - Cohort
Type III Achalasia, EGJ Outflow Obstruction With Spastic/Hypercontractile Features
RecruitingPhase 4
VZV in the Enteric Nervous System: Pathogenesis and Consequences
Achalasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Transverse Mucosal Incision During POEM and Longitudinal Mucosal Incision During POEM in people with Esophageal Achalasia and Spastic Esophageal Motility Disorders, run by Universidad Nacional de Colombia at 1 site in Colombia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Juan P Alzate, MD, MsC (+573102587912, jpalzategr@unal.edu.co), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Effective Submucosal Tunnel Entry (Seconds) (time frame: During the POEM procedure (Day 0; intraoperative)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026.